---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009915"
form_type: "8-K"
ticker: null
cik: "0001722964"
company_name: "Y-mAbs Therapeutics, Inc."
filed_at: "2024-07-19T23:59:59+00:00"
generated_at: "2026-05-31T19:07:03.070049+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Y-mAbs CFO Bo Kruse to depart July 31; consultancy agreement for transition services through July 2025

## Summary
- Kruse's last employment day is July 31, 2024; he receives a pro-rated 2024 bonus of $151,376 (DKK 1,035,867).
- Pre-September 28, 2022 equity continues vesting per original terms; post-September 28, 2022 equity vests through July 31, 2025.
- Consultancy via Investeringsselskabet GH ApS begins August 1, 2024 for one year, with a fixed monthly fee of $43,251 (DKK 295,967 excl. VAT).
- Consulting covers financial operations and corporate governance; Kruse must assist with litigation arising from his tenure.

## SEC filing metadata
- accession: 0001558370-24-009915
- form_type: 8-K
- cik: 0001722964
- company_name: Y-mAbs Therapeutics, Inc.
- filed_at: 2024-07-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009915/0001558370-24-009915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009915/ymab-20240716x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009915
- JSON: https://secwatch.observer/filing/0001558370-24-009915.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009915.txt

## Key facts
- Executive change
  Bo Kruse resigned as Executive Vice President, Chief Financial Officer, Treasurer and Secretary at Y-mAbs Therapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief Financial Officer, Treasurer and Secretary
  source text: On July 16, 2024, in connection with the previously-disclosed resignation of Bo Kruse, the former Executive Vice President, Chief Financial Officer, Treasurer and Secretary of Y-mAbs Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009915/0001558370-24-009915-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.